Cargando…
Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study
BACKGROUND: The long-term risks and time trends of subsequent primary neoplasms (SPNs) among Ewing (ES) and osteosarcoma (OS) survivors are not fully understood. METHODS: We performed a nationwide study of all ES and OS patients identified in the Swedish Cancer Registry from 1958 to 2015 with up to...
Autores principales: | Hesla, Asle Charles, Discacciati, Andrea, Tsagkozis, Panagiotis, Smedby, Karin E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156510/ https://www.ncbi.nlm.nih.gov/pubmed/32066914 http://dx.doi.org/10.1038/s41416-020-0748-3 |
Ejemplares similares
-
Current Status of Management and Outcome for Patients with Ewing Sarcoma
por: Hesla, Asle Charles, et al.
Publicado: (2021) -
Transcriptome profiling of Ewing sarcomas – treatment resistance pathways and IGF‐dependency
por: Chen, Yi, et al.
Publicado: (2020) -
TERT promoter mutation is an objective clinical marker for disease progression in chondrosarcoma
por: Zhang, Yifan, et al.
Publicado: (2021) -
Ewing sarcoma of the mobile spine; predictive factors for survival, neurological function and local control. A Scandinavian sarcoma group study with a mean follow-up of 12 years
por: Hesla, Asle Charles, et al.
Publicado: (2018) -
Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas
por: Brodin, Bertha A., et al.
Publicado: (2019)